Using aerosolized therapy to treat metastatic lung cancer
Official title: Aerosolized Epigenetic Therapy for Metastatic Lung Cancer
Funded at Nob Hill Therapeutics, INC. · NIH-10931496 · Data updated 2026-11-12
This study is exploring a new way to treat metastatic lung cancer by using a special inhaled therapy that may help wake up genes in cancer cells, and it's designed for patients looking for more effective treatment options.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nob Hill Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Albuquerque, UNITED STATES) |
| Project start | September 19, 2023 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $1,138,913 |
| NIH project number | 5R44CA281538-02 |
| Project ID | NIH-10931496 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic lung cancer, particularly those who have not responded well to traditional therapies.
✕Less likely to help
Patients with early-stage lung cancer or those whose cancer has not metastasized may not benefit from this research.
What this research studies
This research investigates a novel approach to treating metastatic lung cancer by using aerosolized epigenetic therapy. The therapy aims to reverse the methylation of genes that are silenced in cancer cells, potentially leading to tumor regression. By utilizing FDA-approved drugs like 5-azacytidine and 5-aza-2’-deoxycytidine, the study seeks to enhance the effectiveness of existing treatments. Patients will receive this therapy through inhalation, allowing for targeted delivery to the lungs.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that improves survival rates and quality of life for patients with metastatic lung cancer.
How similar studies have gone: While the use of epigenetic therapy in solid tumors is still emerging, there have been successful applications in blood-borne cancers, suggesting potential for similar success in lung cancer.
Where this research is happening
-
Nob Hill Therapeutics, INC.
Albuquerque, United States Active
Researchers
- Principal investigator: Reed, Matthew — Nob Hill Therapeutics, INC.
- Study coordinator: Reed, Matthew
Related research
Other NIH-funded projects on the same topics.
-
ECM-targeted theranostic treatment for metastatic lung cancer
A new therapy aims to deliver cancer-fighting agents directly to the tumor environment in people with metastatic lung cancer.
-
Targeted T cell therapy for metastatic lung cancer with mutated KRAS
A personalized therapy uses engineered T cells to attack KRAS-mutated metastatic non-small cell lung cancer in patients.
-
Supportive Care for Lung Cancer Patients with Targeted Therapy
A patient-facing program tests a palliative care approach tailored for people living with oncogene-driven metastatic lung cancer to help with uncertainty, self-care, and discussions about goals and values.
-
LiveWell — DBT skills training for people living with metastatic lung cancer
This is an eight-session, one-on-one online program that teaches Dialectical Behavior Therapy skills to help people living with metastatic lung cancer handle distress, symptoms, and relationships.
-
Engineered T cells that target KRAS-mutated metastatic lung cancer
This project uses specially engineered immune cells to try to find and kill metastatic lung cancers that have KRAS gene mutations.
-
Improving care for patients with advanced lung cancer using personalized approaches
This study is looking to improve support for people with metastatic lung cancer who have certain genetic mutations by testing a new way to help them feel more comfortable and make better decisions about their care, based on what they and their doctors think is important.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.